尿激酶联合低分子肝素治疗不稳定性心绞痛的临床疗效分析

目的：探讨尿激酶联合低分子肝素治疗不稳定性心绞痛(UAP)的临床疗效。方法：将63例UAP患者随机分为溶栓治疗组及常规治疗组，溶栓治疗组(33例)应用尿激酶联合低分子肝素治疗，观察心绞痛发作频率、发作问期、心电图ST段改变以及出凝血检测等，并与常规治疗组(30例)进行比较。结果：溶栓治疗组与常规治疗组的心绞痛发作频率、发作间期及心电图ST段均具有显著性差异，两组用药前、后KPlT、PLT及PT实验监测指标均无显著性差异。结论：尿激酶联合低分子肝素治疗不稳定型心绞痛简单、安全、临床疗效确切，值得在基层医院推广应用。

The Clinical Effects of Unstable Angina Pectoris Treated by Urokinase Combination with Low Molecular Weight Heparins

Objective: To discuss the clinic effects of urokinase combination with low molecular weight heparins treating unstable angina pectoris (UAP). Methods: Sixty-three patients with UAP were randomly divided thrombolysis therapeutic group (TTP) and routine therapeutic group (RTP). TTP (33 cases) was treated by Urokinase combination with low molecular weight heparins; UAP attack frequency, interval and ST segments alteration of electrocardiograph were observed. All results were compared with TTP (30 cases). Results: Two groups have significant differences in UAP attack frequency and interval and ST segments alteration; there have no significant differences in all experimental parameters of hemorrhage and blood coagulation. Conclusions: It is a simple, safety and precisely clinic effect that using Urokinase combination with low molecular weight heparins for treating UAP.